BOS
BMY.RT

Bingham Osborn & Scarborough’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bingham Osborn & Scarborough’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,000
Closed -$34K – 172
2020
Q3 		$34K Buy
+15,000
New +$42.8K ﹤0.01% 162

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bingham Osborn & Scarborough's BMY.RT Position: Q4 2020 in Review

Bingham Osborn & Scarborough sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 15,000 shares — an estimated $34K sold.

Bingham Osborn & Scarborough first reported a position in BMY.RT in Q3 2020 and held it in 1 quarter. The position peaked at $34K in Q3 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Bingham Osborn & Scarborough reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 15,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $34K.
  • Bingham Osborn & Scarborough first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 1 quarter.
  • Bingham Osborn & Scarborough's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $34K in Q3 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2020, filed 11 Feb 2021.